帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Prognostic Impact and Clinicopathological Significance of TIM-3 and LAG-3 Expressions in Laryngeal Squamous Cell Carcinoma.
Prognostic Impact and Clinicopathological Significance of TIM-3 and LAG-3 Expressions in Laryngeal Squamous Cell Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
TIM-3 和 LAG-3 表达与喉癌不良结局相关,尤其是在免疫浸润有限的肿瘤中。这些发现具有探索性,支持进一步开展多中心研究以验证其预后价值及潜在的免疫治疗相关性。证据等级:3。
免疫检查点分子的研究日益增多,反映了其在癌症发病机制中的关键作用。尽管PD-1、PD-L1和CTLA-4在头颈癌中已被广泛研究,但结果仍不令人满意,凸显了对新型预后标志物和治疗靶点的需求。本研究评估了TIM-3和LAG-3表达在喉鳞状细胞癌中的预后意义。
对2016年至2018年间因喉鳞状细胞癌接受开放性喉部分切除术或全喉切除术的50例患者进行了回顾性分析。通过免疫组织化学方法评估肿瘤标本中TIM-3和LAG-3的表达情况,以及总体免疫细胞浸润程度。采用Kaplan-Meier法和多变量Cox回归模型进行生存分析。
TIM-3表达在整个队列中未显示出显著的预后影响,但在低至中度免疫浸润亚组中与较差的总生存期相关(p = 0.045)。LAG-3阳性与整个队列中无复发生存期缩短相关(p = 0.015),并且在低/中度浸润亚组中与总生存期和无复发生存期均相关(分别为p = 0.029和p = 0.016)。多变量Cox回归提示LAG-3是复发的独立预测因子,而TIM-3仅在低/中度免疫浸润亚组中显示出对总生存期的影响。
Fifty patients who underwent open partial or total laryngectomy for laryngeal squamous cell carcinoma (2016-2018) were retrospectively analyzed. Tumor specimens were assessed by immunohistochemistry for TIM-3 and LAG-3 expressions, as well as overall immune infiltration. Survival analyzes were performed using Kaplan-Meier and multivariable Cox regression models.
TIM-3 expression showed no significant prognostic impact in the overall cohort but was associated with worse overall survival in the low-to-moderate immune infiltration subgroup ( p = 0.045). LAG-3 positivity correlated with reduced recurrence-free survival in the full cohort ( p = 0.015) and with both overall and recurrence-free survival in the low/moderate infiltration subgroup ( p = 0.029 and p = 0.016, respectively). Multivariable Cox regression suggested LAG-3 as an independent predictor of recurrence, while TIM-3 showed an effect on overall survival only in the low/moderate immune infiltration subgroup.
TIM-3 and LAG-3 expressions are associated with adverse outcomes in laryngeal cancer, particularly in tumors with limited immune infiltration. These findings are exploratory and support further multicenter studies to validate their prognostic and potential immunotherapeutic relevance. LEVEL OF EVIDENCE: 3.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。